Market Newsdesk

CALGARY, Alberta, Nov. 17, 2020 (GLOBE NEWSWIRE) — News Release – TC Energy Corporation (TSX, NYSE: TRP) (TC Energy or the Company) will host its annual Investor Day in a virtual format today. The Company will provide a financial update and review strategic plans for its natural gas pipelines, liquids pipelines and power and storage businesses in Canada, the United States and Mexico.

“Despite the challenges brought about by COVID-19, our $100 billion portfolio of high-quality, long-life energy infrastructure assets remain resilient as evidenced by near record financial results expected again in 2020,” said Russ Girling, TC Energy’s president and chief executive officer. “Looking forward, we continue to advance $37 billion of commercially secured projects that will expand and extend our asset footprint across North America. Notably, these projets are underpinned by cost of service regulation and/or long-term, take-or-pay contracts.”

“Our secured capital program, along with a robust portfolio of other projects under development, is expected to drive future growth in earnings and cash flow per share. Based on the confidence we have in our business plan, we are reaffirming that we expect to grow our common share dividend at an annual rate of eight to 10 per cent in 2021 and five to seven per cent thereafter,” added Girling. “Our dividend outlook is in line with our historical approach to capital allocation and consistent with average annual increases in the dividend since 2000.”

Looking forward, TC Energy is well positioned to capture significant additional growth opportunities that are expected to arise as the world both consumes more energy and transitions to a less carbon intensive energy mix. Our network of critical energy infrastructure will be used extensively for decades to come and continue to generate significant in-corridor growth potential. As the world transitions to a low-carbon future, new prospects are expected to emerge. With a deep understanding of energy markets, strong stakeholder relationships, significant financial capacity, and extensive technical expertise across a broad range of energy sources including natural gas, crude oil, nuclear, hydro, wind, solar and other emerging technologies, we expect to continue to grow our portfolio in a manner that aligns with our risk preferences, return expectations and organizational capabilities.

On October 29, 2020, TC Energy announced that its Board of Directors declared a quarterly dividend of $0.81 per common share for the quarter ending December 31, 2020. The quarterly amount equates to $3.24 per common share on an annualized basis and represents an eight per cent increase over the amount declared in 2019. TC Energy’s Board of Directors has increased the common share dividend in each of the last twenty years, from $0.80 per common share in 2000 to $3.24 per common share in 2020, resulting in an average annual increase of seven per cent. The current common share dividend equates to a dividend yield of approximately 5.75 per cent based on the closing price of TC Energy’s common shares on the Toronto Stock Exchange on November 16, 2020.

“With significant internally generated cash flow and continued access to capital markets on compelling terms, we are well positioned to prudently fund our $37 billion secured capital program in a manner that is consistent with maintaining our strong credit profile and targeted credit metrics,” concluded Girling.

Today’s virtual event is scheduled from 7:30 a.m. to 11:00 a.m. MST (9:30 a.m. to 1:00 p.m. EST). Interested parties may view the webcast live from TC Energy’s website at TCEnergy.com/InvestorDay or directly at https://webcast.fmav.ca/tcenergy2020/. The webcast will also be posted online for replay following the event.

For anyone wishing to listen by phone, the event will also be accessible by conference call at 1-800-898-3989 (toll free) or 1-416-695-7850 (direct), using passcode 6772091#.

The presentation materials will be available at TCEnergy.com/InvestorDay at 6:00 a.m. MST (8 a.m. EST).

About TC Energy
We are a vital part of everyday life — delivering the energy millions of people rely on to power their lives in a sustainable way. Thanks to a safe, reliable network of natural gas and crude oil pipelines, along with power generation and storage facilities, wherever life happens — we’re there. Guided by our core values of safety, responsibility, collaboration and integrity, our more than 7,500 people make a positive difference in the communities where we operate across Canada, the U.S. and Mexico.

TC Energy’s common shares trade on the Toronto (TSX) and New York (NYSE) stock exchanges under the symbol TRP. To learn more, visit us at TCEnergy.com.

FORWARD-LOOKING INFORMATION

This release contains certain information that is forward-looking and is subject to important risks and uncertainties (such statements are usually accompanied by words such as “anticipate”, “expect”, “believe”, “may”, “will”, “should”, “estimate”, “intend” or other similar words). Forward-looking statements in this document are intended to provide TC Energy security holders and potential investors with information regarding TC Energy and its subsidiaries, including management’s assessment of TC Energy’s and its subsidiaries’ future plans and financial outlook. All forward-looking statements reflect TC Energy’s beliefs and assumptions based on information available at the time the statements were made and as such are not guarantees of future performance. As actual results could vary significantly from the forward-looking information, you should not put undue reliance on forward-looking information and should not use future-oriented information or financial outlooks for anything other than their intended purpose. We do not update our forward-looking information due to new information or future events, unless we are required to by law. For additional information on the assumptions made, and the risks and uncertainties which could cause actual results to differ from the anticipated results, refer to the most recent Quarterly Report to Shareholders and Annual Report filed under TC Energy’s profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission at www.sec.gov.

-30-

Media Inquiries:

Jaimie Harding / Hejdi Carlsen
403-920-7859 or 800-608-7859

Investor & Analyst Inquiries:

David Moneta / Hunter Mau
403-920-7911 or 800-361-6522

PDF available: http://ml.globenewswire.com/Resource/Download/acddf335-8d25-4dc9-a621-f245d9c0a9ad

WASHINGTON, Nov. 17, 2020 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced findings from its Technology segment’s second annual study of corporate legal departments, in partnership with Relativity. Based on a detailed survey and one-on-one interviews by Ari Kaplan with chief legal officers at companies of all sizes, The General Counsel Report 2021: Rising to Today’s Challenges and Building Resilience for the Future, outlines the elevated responsibilities general counsel have taken on amid the pandemic and current social climate.

Notably, the majority of respondents indicated moderate to significant difficulties in navigating today’s top challenges, including widely dispersed workforces, emerging data types, technology adoption and tackling diversity, equity and inclusion. The report shares the strategies counsel are implementing to overcome these and other issues, establish resiliency for the future and adjust to the changing demands of their role. Key findings include:

• Respondents indicated their roles have changed or intensified this year, with many taking on heavier workloads and new responsibilities, largely due to the pandemic. These include decision-making regarding company-wide COVID-19 plans, increased emphasis on risk management, more time on team support and engagement and preparation for an anticipated uptick in litigation.
• Emerging data types and AI applications are beginning to impact legal teams, particularly in the context of litigation and e-discovery, with more than half feeling less than well-prepared to manage these new challenges.
• The pandemic has forced 84 percent of general counsel to fulfill the critical role of chief health officer and/or manage employee well-being. Many of the general counsel surveyed said they are now responsible for assessing and recommending policies to balance maintaining business activities with the health and safety of their employees.
• Many respondents work with a wide range of law firms and outside legal service providers, and 84 percent said they outsource legal work because they lack the necessary in-house expertise for certain matters or technical needs.
• AI use in the legal department has increased since 2019, with 32 percent of respondents indicating they currently use AI for legal functions. Many expressed interest in exploring how to leverage AI for contract management and review needs.
• Some technology initiatives stalled in 2020. One respondent said, “My role is to modernize the law department, but the pandemic has prevented many of those initiatives.”
• Perceptions about technical competence have improved, with 55 percent stating they believe lawyers have adequate knowledge of technology, compared to only 39 percent in 2019. Still, many respondents made a point to distinguish between technology proficiency in using productivity and collaboration tools versus leveraging advanced e-discovery and analytics technologies.

“General counsel have risen to meet the immense challenges that have defined 2020 and solidified their role as critical strategic leaders,” said Daryl Teshima, a Senior Managing Director within FTI Technology. “Last year’s General Counsel Report revealed a marked shift in the role of the GC from the ‘office of no’ to an important contributor to business strategy. The events of this year have further accelerated this shift, with organizations now looking to their in-house legal teams to guide important decisions relating to pandemic response, inclusion, employee wellness, mitigating new and unexpected risks and contributing to the overall success of the business. Our goal with this study is to help counsel better understand this landscape and to facilitate insights that will help them as they take on an endless influx of complex challenges.”

The study also found that corporate legal teams continue to rely heavily on outside partners to fill critical skills and resources gaps. Respondents listed a number of factors that impact how they select outside providers. Specialized expertise and quality of work stood out as the top factors, with cost, relationships and diversity also making the list of considerations.

“One of the goals of The General Counsel Report is to give readers insight into what may affect organizations in the future based on the experiences of chief legal officers, but predicting the turbulent times of 2020 would have been difficult, bordering on the impossible,” said David Horrigan, Discovery Counsel and Legal Education Director at Relativity. “Nevertheless, the general counsel in last year’s study gave us actionable insights into what would happen in 2020, including tremendous risk and the embrace of cloud technologies—and they may not have even realized how prescient and insightful their observations would be for a 2020 remotely connected world. As we look to 2021, The General Counsel Report provides actionable intelligence on issues ranging from the technical competence of legal teams to the latest on inclusion and diversity initiatives.”

Download TheGeneral Counsel Report 2021: Rising to Today’s Challenges and Building Resilience for the Future.

Demographics and methodology

From August 11, 2020 through September 2, 2020, Ari Kaplan personally interviewed 31 general counsel with predominantly Fortune 1000 companies and institutions of higher education. Forty-eight percent have revenues that exceed $1 billion, and 61 percent have over 1,000 employees. While most were in technology and telecommunications (32 percent); 13 percent were from consumer products companies; 13 percent from life sciences; 13 percent from manufacturing; 10 percent from banking, insurance or financial services organizations; 6 percent in higher education; and the remainder were from construction, energy, transportation and travel.

About FTI Consulting

FTI Consulting, Inc. is a global business advisory firm dedicated to helping organizations manage change, mitigate risk and resolve disputes: financial, legal, operational, political & regulatory, reputational and transactional. With more than 6,200 employees located in 28 countries, FTI Consulting professionals work closely with clients to anticipate, illuminate and overcome complex business challenges and make the most of opportunities. The Company generated $2.35 billion in revenues during fiscal year 2019. For more information, visit www.fticonsulting.com and connect with us on Twitter (@FTIConsulting), Facebook and LinkedIn.

About Relativity

At Relativity, we make software to help users organize data, discover the truth, and act on it. Our platform is used by more than 13,000 organizations around the world to manage large volumes of data and quickly identify key issues during litigation, internal investigations, and compliance operations with SaaS platform RelativityOne and Relativity Trace. Relativity has users in 48+ countries from organizations, including the U.S. Department of Justice, and 199 of the Am Law 200. Relativity has been named one of Chicago’s Top Workplaces by the Chicago Tribune for 10 consecutive years. Please contact Relativity at [email protected] or visit http://www.relativity.com for more information.

FTI Consulting, Inc.

555 12^th Street NW
Washington, DC 20004
+1.202.312.9100

Investor
Contact:

Mollie Hawkes
+1.617.747.1791
[email protected]

Media Contact:

Kate Holmes
+1.206.373.6521
[email protected]

TORONTO, Nov. 17, 2020 (GLOBE NEWSWIRE) — QuestCap Inc. (“QuestCap” or the “Company”) (NEO:QSC; OTC:COPRF; FRA:34C1), is pleased to announce that it has initiated the process to change its corporate name to Medi-Volve in conjunction with its transition to a single purpose medical company, previously announced on October 13^th, 2020. This name change is intended to emphasize the Company’s growth in the COVID-19 medical space and demonstrate the Company’s commitment to investing in innovative medical solutions that will combat the pandemic and help restore reality responsibly.

QuestCap has assembled a management team and advisory group of renowned medical experts. This team includes Dr. Lawrence Steinman, Professor of Neurology, Neurological Sciences and Paediatrics at Stanford University and former head of Immunology at Stanford. As well as Dr. Glenn Copeland, is one of North America’s most prominent foot and ankle specialists and founder, chairman, and CEO of Cleveland Clinic Canada. Cleveland Clinic is universally regarded as one of the top three medical institutions in the world.

Their expertise guides the Company’s strategy for combatting the COVID-19 pandemic, including assessing the merit of novel technologies and clinical studies, as well as developing protocols and standards to help restores businesses. Further, this team is currently supporting the development of the Company’s long-term strategy in the medical space outside of pandemic-related initiatives.

In accordance with company policy, QuestCap shareholders have been notified of the proposed name change and will vote to ratify the name change at the next Annual General Meeting (“AGM”), scheduled for December 3, 2020. The name change remains subject to shareholder and regulatory approval.

“As QuestCap completed the transition to a single purpose medical company, our team saw an opportunity to rebrand to Medi-Volve to underscore to the market our singular focus on the world’s largest medical challenge – combatting COVID-19,” says Mr. Doug Sommerville, CEO of QuestCap. “We worked with our internal specialists to develop this new brand that we will champion as we make Medi-Volve an industry leader in the fight against COVID-19.”

About QuestCap Inc.


QuestCap Inc.
 (NEO:QSC; OTC:COPRF; FRA:34C1) seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors. Specifically, QuestCap offers investors a diversified investment in the COVID-19 medical space across three areas; prevention, detection, and treatment.

QuestCap has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space. This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.

QuestCap’s primary focus is the sale of COVID-19 IgG/IgM antibody tests authorized by FDA under an EUA for use by authorized laboratories. This is achieved largely through two acquisitions: 100% of Collection Sites, LLC and 28% of Colombian Sanaty IPS. Collection Sites is setting up a series of COVID-19 testing sites across the United States with appointments and payments handled through the online portal www.testbeforeyougo.com. Sanaty is setting up a series of full-service medical clinics offering a complete COVID-19 testing solution.

For additional information, please contact:

Doug Sommerville, CEO
[email protected]
+1 416-301-5418

For investing inquiries please contact:
Evan Veryard
[email protected]

For US media enquires please contact:
Veronica Welch
[email protected]
+1-508-643-8000

Cautionary Note Regarding Forward-looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, the proposed name change. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

NEITHER THE NEO EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

WEST CHESTER, Penn., Nov. 17, 2020 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it has received the final meeting minutes from the U.S. Food and Drug Administration (FDA) following the Company’s recent Type A meeting to discuss the steps required for resubmission of the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum).

VP-102 is a first-in-class, proprietary drug-device combination for the treatment of molluscum, a viral skin disease affecting approximately six million people, primarily children, in the United States. There are currently no FDA-approved treatments for molluscum. In July, the Company announced that it had received a Complete Response Letter from the FDA requesting additional Chemistry, Manufacturing and Controls (CMC) information as well as Human Factors validation.

“We are encouraged by our productive discussion with the FDA and the FDA’s written meeting minutes, which reflect alignment on the steps to address the CMC issues raised in the CRL as well as the path forward for resubmission of the NDA and the potential approval of VP-102 to treat patients with molluscum,” said Ted White, President and Chief Executive Officer, Verrica. “In addition, our Human Factors study protocol has been reviewed by the FDA and we are preparing to complete that study by the end of the year. We are pleased to reaffirm our expectation to resubmit the NDA for VP-102 pursuant to the statutory 505(b)(1) regulatory pathway in the first quarter of 2021.”

This news follows Verrica’s recent announcement of positive results for VP-102 for the treatment of external genital warts (EGW) in the Phase 2 CARE-1 trial. As previously announced, Verrica intends to request an End-of-Phase 2 meeting with the FDA for VP-102 in EGW in the first quarter of 2021.

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. The Company’s late-stage product candidate, VP-102, is a potential first-in-class drug-device combination product containing a topical therapy for the treatment of molluscum contagiosum. In addition, Verrica has successfully completed a Phase 2 study of VP-102 for the treatment of common warts and a Phase 2 study of VP-102 for the treatment of external genital warts. The Company is also developing VP-103, its third cantharidin-based product candidate, for the treatment of plantar warts. Verrica submitted an NDA for VP-102 for the treatment of molluscum in September 2019. A Complete Response Letter was received from the FDA regarding the NDA for VP-102 on July 13, 2020. In October 2020, Verrica participated in a Type A meeting with the FDA. Verrica expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021. If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name YCANTH™. For more information, visit www.verrica.com.

Forward-Looking Statement
s

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include expectations regarding the Company’s expectations with regard to its interactions and communications with the FDA, the timing for its resubmission of the NDA for VP-102 in the first quarter of 2021, the potential approval of the NDA for VP-102 following resubmission, the potential benefits and potential commercialization of VP-102 for the treatment of molluscum, if approved, and the potential benefits and clinical development plan for VP-102 for the treatment of EGW. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the drug development process and the regulatory approval process, Verrica’s reliance on third parties over which it may not always have full control, uncertainties related to the COVID-19 pandemic and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2019, Verrica’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and other filings Verrica makes with the U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

A. Brian Davis

Chief Financial Officer
484.453.3300 ext. 103
[email protected]

William Windham

Solebury Trout
646.378.2946
[email protected]

Media:

Zara Lockshin

Solebury Trout
646.378.2960
[email protected]

TORONTO, Nov. 17, 2020 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce an expansion licensing transaction of newly-acquired subsidiary Intouch with Health’s (“Intouch”) suite of patient flow and operational visibility solutions to East Suffolk and North Essex NHS Foundation Trust (the “Trust” or “ESNEFT”).

East Suffolk and North Essex NHS Foundation Trust provides hospital and community health care services for Colchester, Ipswich and local areas, including Aldeburgh, Clacton, Halstead, Harwich and Felixstowe community hospitals and Bluebird Lodge near Ipswich, and is the largest NHS organization in the region. This licensing transaction comes as a result of the Trust’s need for a cohesive pre-operative solution to load balance capacity and demand and manage flow across various sites and departments. The Trust had previously been an Intouch client, having licensed Intouch’s Check-in and Flow Manager solutions. As a result of the success of the initial implementation of these products, the Trust has completed an expansion licensing deal with the Company, to acquire the Synopsis Home and Synopsis iQ suite of solutions.

Through the implementation of these solutions, the Trust will be able to meaningfully advance its digital transformation aspirations, intended toward enabling the integration of care systems across facilities to provide enhanced care delivery and patient outcomes. Specifically, the use of the Synopsis product suite will afford the Trust an ability to promote high quality, dynamic outpatient services which accommodate socially distanced care delivery.

The COVID-19 crisis has made it necessary for hospitals to have as many patients stay at home as possible, which must be balanced with the need to continue to carry out urgent elective surgery. Remote pre-operative assessments satisfy that need by supporting social distancing and infection control. Synopsis Home enables trusts to pre-assess at least 60% of their patients remotely. The Trust is following the lead of the Worcestershire Acute Hospitals NHS Trust, who have pre-assessed 100% of their patients remotely since March.

The transition to a virtual clinic format will facilitate a reduction in their requirement of patients to attend hospitals for consultations, improving capacity and load balancing, patient convenience, and the overall care delivery process. These improvements will also extend to long-term care patients who will be proactively managed in their homes, affording improved levels of communication while reducing pressures on clinicians and Trust resources.

The Trust has licensed the multiple-award-winning Synopsis iQ product, providing the ability to share comprehensive pre-operative information with providers, allowing them to care for patients in a blended and seamless manner, managing, on the same integrated platform, those patients who present remotely for consultation alongside those who physical present at one of their hospital sites. Alongside Synopsis iQ, the Trust also plans to license Synopsis Home, enabling patients to complete their pre-operative health questionnaire remotely.

“With this deal, we continue to expand our footprint and reach across the National Health Service. We are delighted that our customers continue to find immense value in our products, especially during a time when minimizing the number of patients physically present in the hospital is vital,” said VitalHub CEO Dan Matlow. “We look forward to continuing to provide best-in-class patient flow and operational visibility solutions to healthcare organizations on a global basis, both during the pandemic and afterward, as we lead the charge in offering solutions that maximize health system efficiency, benefiting all of the systems, health professionals, and the patients.”

ABOUT
EAST SUFFOLK AND NORTH ESSEX NHS FOUNDATION TRUST

East Suffolk and North Essex NHS Foundation Trust delivers hospital and community health care services for Colchester, Ipswich, and surrounding areas as the largest NHS organization in the region. The Trust was formed on 1 July 2018 through the merger of Colchester Hospital University NHS Foundation Trust and The Ipswich Hospital NHS Trust, and now services Colchester and Ipswich hospitals, Aldeburgh, Clacton, Halstead, Harwich and Felixstowe community hospitals, Bluebird Lodge near Ipswich, and delivers community services in Suffolk.

ABOUT VITALHUB

Software for Health and Human Services providers designed to simplify the user experience & optimize outcomes.

VitalHub provides technology to Health and Human Services providers including; Hospitals, Regional Health Authorities, Mental Health, Long Term Care, Home Health, Community and Social Services. VitalHub solutions span the categories of Electronic Health Record (EHR), Case Management, Care Coordination, Patient Flow & Operational Visibility, and DOCit Mobile Apps.

The Company has a robust two-pronged growth strategy, targeting organic growth opportunities within its product suite, and pursuing an aggressive M&A plan. Currently, VitalHub serves 275+ clients across Canada, USA, UK, Australia, Qatar, and Latvia. VitalHub is based in Toronto, Canada, with an offshore development hub in Sri Lanka. The Company is publicly traded on the TSX Venture Exchange under the symbol “VHI”.

CAUTIONARY STATEMENT

This press release includes forward-looking statements regarding the Corporation and its business, which may include, but is not limited to, statements with respect to the appointment of a new directors. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the technology industry, failure to obtain regulatory or shareholder approvals, market conditions, economic factors, the equity markets generally and risks associated with growth and competition. Although the Corporation has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Corporation undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

CONTACT INFORMATION

Dan Matlow
Chief Executive Officer, Director
(416) 727-9061
[email protected]

SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, will be presenting at the San Antonio Breast Cancer Virtual Symposium (SABCS) set to take place December 8-11, 2020.

The data presented will be a part of the event’s Spotlight Session Poster Presenters. Details of the presentation are as follows:

Title –
Describing the cancer spectrum in families with CHEK2 pathogenic and likely pathogenic variants by mutation type

Authors – Julia G Moroney, MS, CGC, and Michele S. Basiliere, MS, CGC
Poster number – PS8-18
Date and time – Wednesday, December 9, 2020: 8:00 AM CT

SABCS anticipates publishing abstracts in late November 2020 and posters on December 9, 2020. The poster presentation will also be made available on the Progenity website following the conference.

About Progenity

Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For additional information about Progenity, please visit the company’s website at www.progenity.com.

Investor Contact:

Robert Uhl
Managing Director, Westwicke ICR
[email protected]
(619) 228-5886

Media Contact:

Kate Blom-Lowery
CG Life
media@progenity.com
(619)743-6294

Dallas, Nov. 17, 2020 (GLOBE NEWSWIRE) — Thryv Holdings, Inc. (NASDAQ:THRY), the provider of Thryv^® software, the end-to-end client experience platform for small businesses, today announced that CEO and President Joe Walsh will participate in a virtual fireside chat discussion at the Stephens Annual Investment Conference 2020 on November 19 at 3 p.m. ET.

A live webcast of the Stephens conference presentation will be available on the Thryv investor relations website at investor.thryv.com. An archived replay will be made available for a limited time at the same location following the event. 

About Thryv Holdings, Inc.

The company owns the easy-to-use Thryv® end-to-end customer experience software built for small business that helps over 40,000 SaaS clients with the daily demands of running a business. With Thryv, they can get the job, manage the job and get credit. Thryv’s award-winning platform provides modernized business functions, allowing small-to-medium-sized businesses (SMB) to reach more customers, stay organized, get paid faster and generate reviews. These include building a digital customer database, automated marketing through email and text, updating business listings across the internet, scheduling online appointments, sending notifications and reminders, managing ratings and reviews, generating estimates and invoices and processing payments.

Thryv supports franchise operators and multi-location business owners with Hub by Thryv™, a software console that enables businesses managers to oversee their operations using the Thryv software.

Thryv also connects local businesses to consumer services through our search, display and social media management products, our print directories featuring The Real Yellow Pages® tagline, and our local search portals, which operate under the DexKnows.com®, Superpages.com® and Yellowpages.com URLs and reach some 35 million monthly visitors. For more information about the company, visit thryv.com.

Thryv delivers business services to more than 360,000 SMBs across America that enable them to compete and win in today’s economy.      

Learn more about Thryv on LinkedIn and Medium.

 

Media Contact:

Paige Blankenship

Thryv, Inc.

972.453.3012

[email protected]

 

Investor Contact:

Cameron Lessard 

Thryv, Inc.
    

214.773.7022 

[email protected]   

 

KJ Christopher

Thryv, Inc.

972.453.7068

[email protected]

 

###

Paige Blankenship
Thryv, Inc.
972.453.3012
[email protected]

VANCOUVER, British Columbia, Nov. 17, 2020 (GLOBE NEWSWIRE) — CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a telemedicine company seeking to revolutionize the delivery of healthcare to patients, is pleased to announce that executives from the Company’s management team will be participating in the following upcoming investor conferences:

Canaccord
Genuity
Health and Wellness
Virtual Conference
,

November 23, 2020

• Dr. Essam Hamza, CEO, will be participating in the Digital Health and Telemedicine Panel at 9 a.m. EST
• Karen Adams, Chief Health Innovation Officer, will be participating in the Mental Health Services Panel at 11a.m. EST

To register for this virtual conference, please contact your Canaccord representative.

Desjardins Digital Healthcare Conference,

November 24, 2020

• Dr. Essam Hamza, CEO will be presenting the Company and business at 1:45 p.m. EST

To register for this conference, please contact your Desjardins representative.

About CloudMD Software & Services

CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SAAS based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 500 clinics, almost 4000 licensed practitioners and 8 million patient charts across North America.

ON BEHALF OF THE BOARD OF DIRECTORS

“Dr. Essam Hamza, MD”

Chief Executive Officer

FOR ADDITIONAL INFORMATION CONTACT:

Julia Becker

VP, Investor Relations

Email: [email protected]

Forward Looking Statements

This news release contains forward-looking statements that are based on CloudMD’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business. Although CloudMD believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and CloudMD undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

The
TSX Venture
Exchange does not accept responsibility for the adequacy or accuracy of this release.

HOUSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors and other cancers, today announced its chief executive officer, David Arthur, will participate in A.G.P.’s Virtual Healthcare Symposium on Thursday, November 19, 2020.

Mr. Arthur will host virtual one-on-one meetings with investors registered to attend the conference to discuss Salarius’ business, recent achievements, and anticipated clinical milestones. The Company’s lead drug candidate, seclidemstat, is an oral medication that inhibits lysine-specific demethylase 1 (LSD1), an enzyme that is over-produced in some cancers and can promote disease progression. Seclidemstat is being studied in two ongoing Phase 1/2 clinical trials — the first, in patients with relapsed or refractory Ewing sarcoma, a deadly bone and soft tissue cancer primarily diagnosed in children and young adults, and the second, in patients with advanced solid tumors (AST). Early clinical data suggests that that patients can be treated at dose levels that produce drug concentrations similar to concentrations where seclidemstat showed anti-tumor activity in preclinical models.

Salarius previously disclosed that a refractory Ewing sarcoma patient treated with seclidemstat for six months demonstrated a reduction of over 80% in prospectively defined target lesions. Target lesions generally represent a patient’s largest measurable tumors.

For questions and inquiries regarding the conference or to register for a one-on-one meeting, please contact a registered A.G.P. representative or email A.G.P. Events at [email protected].

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients that need them the most. Salarius’ lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma, for which it has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1/2 clinical study in advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius previously disclosed that a refractory Ewing sarcoma patient treated with seclidemstat for six months demonstrated a reduction of over 80% in prospectively defined target lesions. Target lesions generally represent a patient’s largest measurable tumors. However, at eight weeks, an increase in non-target lesions resulted in an overall patient classification of progressive disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST). Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also the recipient of an $18.7 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com or follow the Company on Twitter and LinkedIn.

Forward-Looking Statements 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements may be identified by terms such as “will,” “could,” “believe,” “plan,” “will,” “expect,” “target,” and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, the potential of seclidemstat as a potential treatment for Ewing-related sarcomas; the ability of seclidemstat to demonstrate drug activity; the ability of and degree to which seclidemstat could have a significant impact on the treatment of Ewing sarcoma, as well as other sarcomas with related Ewing sarcoma biology; and the safety profile of seclidemstat in any indication. Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the ability of Salarius to raise additional capital to meet its business operational needs and to achieve its business objectives and strategy; Salarius’ ability to project future capital needs and cash utilization; available sources of cash, including from CPRIT and its equity line; future clinical trial results; that the results of studies and clinical trials may not be predictive of future clinical trial results; the sufficiency of Salarius’ intellectual property protection; risks related to the drug development and the regulatory approval process; the competitive landscape and other industry-related risks; market conditions which may impact the ability of Salarius access capital under its equity line; the possibility of unexpected expenses or other uses of Salarius’ cash resources; and other risks described in Salarius’ filings with the Securities and Exchange Commission, including those under the heading “Risk Factors.” The forward-looking statements contained in this press release speak only as of the date of this press release and are based on management’s assumptions and estimates as of such date. Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.

Contact

Tiberend Strategic Advisors, Inc.
Maureen McEnroe, CFA/Miriam Miller (investors)
(212) 375-2664 / 2694
[email protected]
[email protected]

Johanna Bennett (media)
(212) 375-2686 
[email protected]